Mounjaro (Tirzepatide) in Canada: Cost, Coverage and How It Compares
Last reviewed 2026-09-24
Mounjaro is tirzepatide, a once-weekly injection made by Eli Lilly. It acts on two hormone receptors (GIP and GLP-1), whereas Ozempic acts on one (GLP-1). It needs a prescription.
Approved uses in Canada
Health Canada first approved Mounjaro for adults with type 2 diabetes, alongside diet and exercise. Approval for chronic weight management was added later. Check the current product monograph or ask your pharmacist for the approved uses that apply to you.
Cost and coverage
- Some provincial plans list Mounjaro for type 2 diabetes, often with criteria (for example, other treatments tried first).
- Coverage for weight management alone is uncommon on public plans; private plans vary.
- Without coverage, it typically costs several hundred dollars a month. Compare pharmacy prices before filling.
Mounjaro vs Ozempic
In head-to-head studies in people with type 2 diabetes, tirzepatide produced larger average drops in A1C and body weight than semaglutide 1 mg. Side effects are similar — mostly nausea, diarrhea and reduced appetite. The right choice depends on your health, coverage and your prescriber's advice.
Frequently asked questions
Is Mounjaro the same as Ozempic?
No. Mounjaro is tirzepatide (GIP + GLP-1); Ozempic is semaglutide (GLP-1 only).
Is Mounjaro covered in Ontario?
Coverage rules change. Search it in the Ontario formulary or our provincial coverage checker, and check your private plan.
Official sources
This guide is general information, not medical or financial advice. Program rules and amounts change — confirm with the official source or your pharmacist.